Compare WTI & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTI | CABA |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.4M | 227.2M |
| IPO Year | 2005 | 2019 |
| Metric | WTI | CABA |
|---|---|---|
| Price | $1.63 | $2.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 1.3M | ★ 2.0M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,094,000.00 | N/A |
| Revenue This Year | $0.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $0.99 |
| 52 Week High | $2.59 | $3.67 |
| Indicator | WTI | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 40.48 |
| Support Level | $1.66 | $2.12 |
| Resistance Level | $1.80 | $2.49 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 15.37 | 9.82 |
W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.